Written by: Jenna Kerry, MSc Published: October 25, 2023 Contents Introduction What is Affinity Maturation? How Does Somatic Hypermutation Work? Applications of Affinity Maturation De Novo Proteomic Sequencing of Antibodies Introduction The immune system is a complex system responsible for protecting organisms from various [...]
Written by: Genya Gorshtein, MSc Published: October 18, 2023 Contents Introduction Types of Glycans How are Proteins Glycosylated? Why are Proteins Glycosylated? Protein Glycosylation in the Immune System Importance of Understanding Glycan Profiles of Proteins Discover Glycan Sites and Profiles with Rapid Novor Introduction [...]
In this webinar, you will learn: Workflows for antibody characterization that extend beyond the primary amino acid sequence How to leverage HDX-MS for epitope mapping and SPR for binding kinetics to understand the mechanism of action and maximize the effectiveness of your characterization efforts How to ensure high-quality antibody production with [...]
In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid in bispecific antibody design [...]
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
Our client is a biotechnology company developing therapeutics that target cancer-specific carbohydrate antigens on the surface of tumour cells.
In this webinar, you will learn: About the challenges commonly encountered in antibody discovery campaigns, including non-functional antibodies, limited diversity, developability issues, and immunogenicity. How to de-risk antibody discovery campaigns, while balancing speed and spend Discover how a proteomics and mass spectrometry-based approach to antibody discovery, utilizing REpAb polyclonal sequencing, presents [...]
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
With 22 functional T cell receptor (TCR)Vβ subunit families making up the normal T cell repertoire, signals from these cell surface receptors often determine the fate of normal cells. However, mutations in TCR signaling proteins are frequently associated with peripheral T cell lymphomas (TCLs), including adult T cell leukemia/lymphoma (ATL), which indicates a driving role for TCRs in TCL oncogenesis. As TCL and ATL are clonal in nature, tumour cells typically express a single TCRVβ subunit with no bias in the usage of TCRVβ subunit families. Consequently, targeting the specific TCRVβ subunit presents a promising therapeutic approach that is highly selective and tumour-specific.
Written by: Vanessa Yoon Calvelo, PhD Published: June 6, 2023 Contents The Drug Development Pathway: Overview and Challenges Early Discovery and Development of Therapeutic Antibodies Target Identification and Validation Antibody Discovery and Expression Lead Characterization and Selection Lead Engineering and Optimization Candidate Selection The Drug Development Pathway: Overview [...]
In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]
De novo protein sequencing can support the development of antibody-based reagents, including Dbs and other antibody fragments. Working with the exact amino acid sequence of the mAb can help facilitate the in silico design and conjugation design processes, ensuring accuracy in the final engineered format.
Written by: Vanessa Yoon Calvelo, PhD Published: April 24, 2023 Contents Introduction Functions of Therapeutic Antibodies Functional Assays for Therapeutic Antibodies Functional Characterization in the Therapeutic Antibody Discovery Process Introduction Monoclonal antibodies (mAbs) and related biological products often present as ideal therapeutics largely due to: Their [...]
Written by: Vanessa Yoon Calvelo, PhD Published: April 14, 2023 Contents Introduction Immunochemical Properties of Therapeutic Antibodies Rapid Immunochemical Characterization of Antibodies Introduction Therapeutic antibodies, predominantly monoclonal antibodies (mAbs), are a rapidly expanding class of drugs with over 100 mAb-based biologics now approved for the treatment [...]
In this webinar, you will learn: IVD and immunoassays, supply chain risk management considerations How monoclonal and polyclonal antibody sequencing works, requirements Effective production, validation, and scale-up of recombinant antibody reagents Characterization of mAbs for assay design Abstract Polyclonal antibodies (pAbs) are well known for their robustness and [...]
By conducting an in-depth analysis of non-antigen immunized sheep Ig repertoires via NGS, this data provides further insight into the adaptive immunity of sheep and lays a foundation for future work on immunogenetics and ovine antibody drug development.
In This Webinar, You Will Learn: Why IP is important in the development of antibody-based assets Patent application process and requirements How to strengthen patent applications Applications of Next Generation Protein Sequencing, SPR, and HDX-MS for antibody-related patent applications Abstract In the development of novel and innovative antibody-based [...]
In this webinar, you will learn: How Rapid Novor’s de novo polyclonal sequencing platform REpAb® can accelerate any nanobody development pipeline How SPR and HDX-MS integrate into an antibody discovery and development workflow How to choose optimal lead candidates with SPR and HDX-MS How epitopes can be characterized using SPR and HDX-MS [...]
Antibodies with established, specific targets can be sequenced and utilized to engineer the hinge region and antigen-binding domains with antibody fragments and derivatives. With the sequence information in hand, further steps to optimizing a viable therapeutic approach can be more accessible.
The great debate on the use of in vivo versus in vitro sources and strategies for antibody discovery and generation continues to thrive among antibody research groups. On one side of the debate is the argument for non-animal-derived antibodies due to the technical advancements of current in vitro technologies, and the moral obligation to reduce animal usage. On the other side of the debate is the counterargument for animal-derived antibodies due to their better performance in affinity, specificity, and reduced immunogenicity risk.
To date, near-complete cryo-electron microscopy (cryo-EM) density maps of pTSC were obtained by either employing chemical cross-linking or graphene oxide-coated grids during sample preparation; however, this may not reflect the true native state of pTSC.
In this SPR webinar, you will learn: How SPR works and its unique advantages for kinetic analysis of antibody-antigen interactions Applications of SPR in antibody discovery Functionality of SPR in antibody characterization Abstract Due to their ability to bind biomolecules specifically and tightly, antibodies are highly [...]
De novo protein sequencing provided the research team with insurance by securing the complete amino acid sequence of a therapeutic mAb candidate for ADAD. This mass spectrometry-based protein sequencing technique can be used to obtain the sequence information of any antibody or protein for biomarker discovery, characterization, and validation. Access to this structural information only broadens our understanding of disease pathogenesis and fosters the development of innovative therapeutic or preventative treatments.
Webinar Highlights You will learn: Introduction to the structure and function of the tuberous sclerosis protein complex (pTSC) A novel strategy for isolating and purifying protein complexes from native sources using recombinantly produced Fabs How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid design and engineering of recombinant antibody [...]
As nearly all individuals have pre-existing immunity to influenza viruses, influenza-specific memory B cells will likely be recalled upon COBRA HA vaccination. By comparing the antibody response towards specific wild-type influenza strains and COBRA antigens, we can begin to understand the potential for COBRA-based vaccines to be used in the clinic.
αβTCR-engineered T cells have been applied in clinical trials, specifically directed against cancer/testis antigens. Though the clinical outcomes are promising, only a small proportion of patients benefit from these novel treatments. Lower response rates are partially attributed to a heterogeneous mixture of non-engineered and poorly engineered T cells that remain in the administered therapeutic product. For successful translation of these novel treatments into the clinic, engineering efforts should be reinforced with effective methods for engineered T cell purification and engineered T cell elimination post infusion into patients.
Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.
Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply
Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
The protein sequence is key to understanding the function of a protein target and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.
Antibodies are integral to life sciences research and therapeutic and diagnostics discovery and development. However, they are inherently prone to variability.
Mouse monoclonal antibodies (mAbs) are highly attractive for manipulation for therapeutic applications as their manufacturing is relatively easy and well-established compared to mAbs derived from larger animal models. However, they also pose several challenges which limit their use as therapeutic agents.
In-vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.